Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 218,238,537 papers from all fields of science
Search
Sign In
Create Free Account
CEP 8983
Known as:
CEP-8983
, CEP8983
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Broader (2)
Carbazoles
Phthalimides
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
1 PARP INHIBITORS AS P-GLYOPROTEIN SUBSTRATES
Denise Lawlor
,
Patricia Martin
,
Steven Busschots
,
J. Théry
,
B. Hennessy
,
B. Stordal
2018
Corpus ID: 53666282
The cytotoxicity of PARP inhibitors olaparib, veliparib and CEP-8983 were investigated in two P-glycoprotein overexpressing drug…
Expand
2016
2016
An open-label, dose-escalation study to evaluate the safety and pharmacokinetics of CEP-9722 (a PARP-1 and PARP-2 inhibitor) in combination with gemcitabine and cisplatin in patients with advanced…
A. Awada
,
M. Campone
,
+6 authors
J. Soria
Anti-Cancer Drugs
2016
Corpus ID: 960247
Poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors may potentiate chemotherapy by hindering DNA damage repair pathways. CEP-9722…
Expand
Highly Cited
2014
Highly Cited
2014
PARP Inhibitors as P-glyoprotein Substrates.
Denise Lawlor
,
Patricia Martin
,
+4 authors
B. Stordal
Journal of Pharmacy and Science
2014
Corpus ID: 206153013
The cytotoxicity of PARP inhibitors olaparib, veliparib, and CEP-8983 were investigated in two P-glycoprotein (P-gp…
Expand
2014
2014
Poly(ADP-ribose) polymerase inhibitor CEP-8983 synergizes with bendamustine in chronic lymphocytic leukemia cells in vitro.
Robert L. Dilley
,
Weijie Poh
,
+5 authors
K. Pratz
Leukemia research : a Forum for Studies on…
2014
Corpus ID: 25105290
2013
2013
PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs.
K. Olaussen
,
J. Adam
,
+13 authors
J. Soria
Lung Cancer
2013
Corpus ID: 12526888
2013
2013
Abstract 3282: Poly (ADP) ribose polymerase (PARP) enzyme inhibitor, CEP8983, potentiates bendamustine activity in small cell lung cancer (SCLC).
T. Owonikoko
,
Guojing Zhang
,
P. Yue
,
S. Ramalingam
,
F. Khuri
,
Shi-Yong Sun
2013
Corpus ID: 75912551
Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC Background: Effective therapy for small cell lung…
Expand
2012
2012
Abstract 3115: PARP overactivation predicts the susceptibility of human cancer cells to apoptosis induction by PARP inhibitors
J. Michels
,
I. Vitale
,
+6 authors
G. Kroemer
2012
Corpus ID: 76377062
Chemical inhibitors of poly(ADP)ribose (PAR) polymerases (PARP) have generated raising expectations in cancer treatment, either…
Expand
Highly Cited
2007
Highly Cited
2007
The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity
S. Miknyoczki
,
Hong Chang
,
+10 authors
B. Ruggeri
Molecular Cancer Therapeutics
2007
Corpus ID: 16462342
The effect of the potent and selective poly(ADP-ribose) (PAR) polymerase-1 [and PAR polymerase-2] inhibitor CEP-8983 on the…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE
or Only Accept Required